STOCK TITAN

Cellectar Biosciences Inc - CLRB STOCK NEWS

Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.

About Cellectar Biosciences Inc.

Cellectar Biosciences Inc. (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company dedicated to advancing the treatment of cancer through its proprietary Phospholipid Drug Conjugate™ (PDC) platform. This innovative technology is designed to deliver therapeutic payloads directly to cancer cells, offering enhanced efficacy and reduced off-target effects. By leveraging its PDC platform, the company aims to address significant unmet medical needs in oncology while improving patient outcomes.

Core Technology: The PDC Platform

Cellectar’s PDC platform is based on proprietary phospholipid ether analogs, which demonstrate highly selective uptake and retention in cancer cells. This precision-targeting capability enables the development of therapies that minimize damage to healthy tissue, making it a promising approach for both therapeutic and diagnostic applications. The platform supports the delivery of various oncologic payloads, including radioisotopes, chemotherapeutics, and other therapeutic agents.

Pipeline and Lead Product Candidates

The company’s product pipeline includes a diverse range of assets designed to target hematologic malignancies and solid tumors:

  • Iopofosine I 131: A small-molecule PDC utilizing iodine-131, a cytotoxic radioisotope, to target and destroy cancer cells. This lead asset is under evaluation in clinical trials for multiple indications, including Waldenstrom’s macroglobulinemia (WM), multiple myeloma, and central nervous system lymphoma. It has received Orphan Drug and Fast Track Designations from the U.S. FDA for various cancer indications.
  • CLR 121225: An actinium-225-based alpha-emitting radioconjugate targeting solid tumors such as pancreatic and triple-negative breast cancers. This program aims to leverage the precision of alpha emitters for enhanced efficacy in difficult-to-treat cancers.
  • CLR 121125: An iodine-125 Auger-emitting radioconjugate with applications in triple-negative breast, lung, and colorectal cancers. Auger emitters offer unparalleled precision, delivering therapeutic effects at the subcellular level.

Strategic Focus and Market Position

Cellectar’s strategy combines internal drug development with external collaborations to maximize the potential of its PDC platform. By partnering with other biopharmaceutical companies, Cellectar expands the applicability of its technology while diversifying its revenue streams. The company’s focus on radiopharmaceuticals positions it within a niche but growing segment of the oncology market, where demand for targeted therapies is increasing.

Industry Challenges and Opportunities

Operating in the competitive oncology sector, Cellectar faces challenges such as regulatory approvals, supply chain complexities for rare isotopes, and significant capital requirements for clinical development. However, its proprietary platform, coupled with a robust pipeline and strategic collaborations, provides a strong foundation for addressing these challenges. The company’s focus on unmet medical needs and orphan drug markets further enhances its growth potential.

Commitment to Innovation

With a mission to revolutionize cancer treatment, Cellectar continues to advance its pipeline and explore new applications for its PDC platform. Its dedication to innovation, combined with a strategic approach to development and commercialization, underscores its potential to make a lasting impact in oncology.

Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) announced its participation in upcoming investor conferences, including the Roth Capital Partners 34th Annual Conference on March 15, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022. Both events will feature fireside chats and opportunities for 1x1 meetings with investors. Cellectar is focused on developing innovative cancer treatments using its proprietary Phospholipid Drug Conjugate platform, with ongoing studies on its lead asset, iopofosine, targeting various cancer types, including Waldenstrom's macroglobulinemia and pediatric cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) has appointed Chad Kolean as Chief Financial Officer and promoted Jarrod Longcor to Chief Operating Officer. Kolean returns after a successful tenure at other companies, aiming to leverage his extensive industry experience. Longcor, with six years at Cellectar, will oversee operations and strategic growth efforts as the company prepares for a potential NDA filing for its drug targeting Waldenstrom’s macroglobulinemia. The company also plans a pivotal trial assessment of its lead compound, iopofosine I-131, in the near future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
management
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) announced participation in a fireside chat at the H.C. Wainwright Bioconnect conference, scheduled for January 10-13, 2022. CEO Jim Caruso and CBO Jarrod Longcor will discuss company updates, with the chat available on-demand from 7:00 am ET on January 10.

Cellectar is focused on developing targeted cancer therapies, leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) platform. The pipeline includes iopofosine for relapsed or refractory cancers, currently in pivotal studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) presented promising data from 11 patients in its ongoing Phase 2 CLOVER-1 study of iopofosine I-131 for treating refractory multiple myeloma at the ASH Annual Meeting. The trial showed an overall response rate (ORR) of 45.5%, with a clinical benefit rate (CBR) of 72.7% and a disease control rate (DCR) of 100%. In a subgroup of quad/penta drug refractory patients, the ORR reached 80%.

Despite these positive results, cytopenias were noted as the primary adverse events. The company anticipates sharing further data as the study progresses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Summary

On December 8, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced a poster presentation at the ASH Annual Meeting, showcasing data from the ongoing Phase 2 CLOVER-1 study of iopofosine I-131. The study focuses on eleven patients with triple-class refractory multiple myeloma, highlighting preliminary efficacy and safety results. The poster session will occur on December 11, 2021. Iopofosine is designed for targeted cancer treatment and is undergoing multiple clinical studies, including a pivotal trial for Waldenstrom's macroglobulinemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
-
Rhea-AI Summary

Cellectar Biosciences (CLRB) announced positive results from a Phase 1 study of iopofosine I-131 for treating pediatric relapsed cancers, specifically high-grade gliomas and soft tissue sarcomas. The study showed promising tumor responses, with patients experiencing over 5 months of progression-free survival, almost double the historical norm of 2-3 months. The Data Monitoring Committee has approved dose escalations, suggesting the treatment is safe and tolerable. Cellectar plans to engage with the FDA on potential next steps for regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) reported Q3 financial results for the period ending September 30, 2021. The company completed Part A of a safety study for iopofosine in combination with external beam radiation for head and neck cancer. Preliminary data indicates safety and tolerability. They secured a $2 million NIH Phase II SBIR grant to support iopofosine’s pivotal study in Waldenstrom’s macroglobulinemia. Cash reserves stood at $40.3 million, but the company posted a net loss of $5.8 million for Q3, widening from a $3.9 million loss in 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) announced Dr. Laurence Reilly as interim chief medical officer, succeeding Dr. John Friend, who departs for personal reasons. Dr. Reilly brings extensive experience in hematological oncology and is expected to lead Cellectar's clinical development programs, including the pivotal trial for iopofosine I-131 in treating Waldenstrom’s macroglobulinemia. The company remains financially stable and aims to advance its cancer treatment pipeline through ongoing trials and collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
management
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) has announced a collaboration with BBK Worldwide to enhance patient support services for participants in its clinical studies. This initiative aims to provide comprehensive concierge services, including transportation and assistance with reimbursement for cancer patients. The focal point of this collaboration is the ongoing pivotal study of iopofosine I-131 for Waldenstrom's macroglobulinemia. Cellectar is also engaged in additional clinical studies involving iopofosine for other hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) announced the initiation of an expansion cohort for the iopofosine I-131 study in patients with relapsed or refractory head and neck cancer. Following the completion of a safety phase, the University of Wisconsin will assess the potential of iopofosine combined with external beam radiation therapy (EBRT) to reduce radiation doses while maintaining tumor response. The study aims to enroll up to 24 patients and is part of a broader evaluation of iopofosine in various cancers. The company remains optimistic about the treatment's efficacy and safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none

FAQ

What is the current stock price of Cellectar Biosciences (CLRB)?

The current stock price of Cellectar Biosciences (CLRB) is $0.292 as of April 1, 2025.

What is the market cap of Cellectar Biosciences (CLRB)?

The market cap of Cellectar Biosciences (CLRB) is approximately 13.6M.

What is Cellectar Biosciences' core technology?

Cellectar Biosciences utilizes its proprietary Phospholipid Drug Conjugate (PDC) platform to deliver therapeutic payloads directly to cancer cells, enhancing efficacy and minimizing off-target effects.

What is iopofosine I 131?

Iopofosine I 131 is Cellectar's lead asset, a small-molecule PDC that uses iodine-131 to target and destroy cancer cells. It is under clinical evaluation for multiple cancer indications.

What types of cancers does Cellectar target?

Cellectar focuses on both hematologic malignancies, such as multiple myeloma and Waldenstrom’s macroglobulinemia, and solid tumors, including pancreatic, triple-negative breast, and colorectal cancers.

How does Cellectar differentiate itself from competitors?

Cellectar’s proprietary PDC platform enables precise targeting of cancer cells, reducing off-target effects and improving safety. Its focus on radiopharmaceuticals and orphan drug markets further differentiates it.

What are the key challenges Cellectar faces?

Cellectar faces challenges such as regulatory hurdles, isotope supply chain complexities, and the high capital requirements typical of clinical-stage biopharmaceutical companies.

What is CLR 121225?

CLR 121225 is an actinium-225-based radioconjugate targeting solid tumors. It leverages alpha-emitting isotopes for precision therapy in cancers with significant unmet needs.

What is the significance of the PDC platform?

The PDC platform enables targeted delivery of diverse therapeutic payloads to cancer cells, improving efficacy and safety. It supports both internal drug development and external collaborations.

What regulatory designations has Cellectar received?

Cellectar’s lead asset, iopofosine I 131, has received Orphan Drug and Fast Track Designations from the U.S. FDA for various indications, highlighting its potential in addressing unmet medical needs.
Cellectar Biosciences Inc

Nasdaq:CLRB

CLRB Rankings

CLRB Stock Data

13.61M
45.32M
1.64%
11%
4.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK